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ABSTRACT
Objectives: To update the evidence for the efficacy
and safety of (b)biological and (ts)targeted-synthetic
disease-modifying anti-rheumatic drugs (DMARDs) in
patients with axial spondyloarthritis (axSpA) to inform
the 2016 update of the Assessment of
SpondyloArthritis international Society/European
League Against Rheumatism (ASAS/EULAR)
recommendations for the management of axSpA.
Methods: Systematic literature review (2009–2016)
for randomised controlled trials (RCT), including long-
term extensions, strategy trials and observational
studies (the latter was only for safety assessment and
a comparator was required). Interventions were any
bDMARD or tsDMARD. All relevant efficacy and safety
outcomes were included.
Results: 76 papers and 24 abstracts fulfilled the
inclusion criteria. Large treatment effects were found
both in radiographic axSpA (r-axSpA) and non-
radiographic axSpA (nr-axSpA) for all tumour necrosis
factor inhibitors (TNFi) (NNT to achieve ASAS40
response ranged between 2.6–5.2 for r-axSpA and
2.3–5.4 for nr-axSpA). For nr-axSpA, efficacy was
superior for those who had objective signs of
inflammation (positive C reactive protein or
inflammation on MRI-SI). Secukinumab 150 mg has
shown efficacy in two phase 3 RCTs (NNT to achieve
ASAS40 response: 3.4 and 4.0). Ustekinumab and
tofacitinib have shown positive results in phase
2/proof-of-concept trials; trials with apremilast,
rituximab, interleukin (IL)-6 antagonists and abatacept
have failed their primary end points. New (unknown)
safety signals were not found in the trials but long-
term observational safety data for TNFi are still scarce.
Conclusions: New evidence supports the efficacy and
safety of TNFi both in r-axSpA and nr-axSpA.
Secukinumab is the first drug targeting the IL-17
pathway in r-axSpA that has shown efficacy.
INTRODUCTION
In 2003, the Assessment of SpondyloArthritis
international Society (ASAS) published the
ﬁrst consensus statement on the use of
tumour necrosis factor inhibitors (TNFi) for
treating patients with radiographic axial
spondyloarthritis (r-axSpA; formerly-labelled
ankylosing spondylitis (AS)) as deﬁned by
the modiﬁed New York criteria—mNY).1 2
The rapidly evolving ﬁeld demanded regular
updates; the ﬁrst was published in 2006 and
the second in 2010.3 4
A better recognition of early forms of the
disease (not captured by the mNY) has moti-
vated the development and validation of the
ASAS axial spondyloarthritis (axSpA) classiﬁ-
cation criteria, which aggregate both patients
with non-radiographic (nr-axSpA) and radio-
graphic axial SpA (r-axSpA), as a continuous
disease spectrum with similar clinical features
and a common genetic background.5
Thereafter, compelling evidence has shown a
similar disease burden of patients with
r-axSpA and nr-axSpA and the ﬁrst trials in
nr-axSpA have also shown good treatment
effects.6 7 This has ﬁnally led to the inclusion
of the entire spectrum of axSpA in the 2010
update of the recommendations for the use
of TNFi.4
Since the last systematic literature review
(SLR) informing the 2010 update,8 a large
number of trials have been performed that
further expanded the range of available
therapeutic options, including both bio-
logical disease modifying antirheumatic
drugs (bDMARDs) targeting new pathways
Sepriano A, et al. RMD Open 2017;3:e000396. doi:10.1136/rmdopen-2016-000396 1
Spondyloarthritis
group.bmj.com on March 31, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
and, more recently, targeted-synthetic DMARDs
(tsDMARDs).9 Landmark trials of TNFi including only
patients with early nr-axSpA were undertaken and the
ﬁrst biosimilar (CT-P13) has been compared to its ori-
ginator drug. Studies addressing strategies for biological
treatment tapering have been performed and data from
long-term extensions of the ﬁrst trials on TNFi have
become available. In addition, there are now more
observational data on long-term safety of these drugs in
clinical practice.
In 2010, two separate sets of recommendations had
been released: (1) the international ASAS recommenda-
tions for the use of TNFi in patients with axSpA;4 and
(2) the ASAS/European League Against Rheumatism
(EULAR) recommendations for the management of
AS,10 which was an update of the ﬁrst recommendations
issued.11 Since then, many new developments (extend-
ing also to non-biological therapies) have prompted a
collaborative effort of ASAS and the EULAR to update
the recommendations for the management of axSpA,
which for the ﬁrst time incorporate the different aspects
of management into one set and also cover the whole
spectrum of the disease (2016 update of the
ASAS-EULAR management recommendations for axial
Spondyloarthritis. van der Heijde D, Ramiro S,
Landewé R, et al. Ann Rheum Dis 2016, submitted for
publication). The overarching aim of this SLR was to
inform the ASAS/EULAR task force on the new evi-
dence for the efﬁcacy and safety of treatment with
bDMARDs and tsDMARDs. In this manuscript, the
results of SLR on bDMARDs and tsDMARDs are
described, whereas the results for the SLR on non-
pharmacological and non-biological pharmacological
treatments are shown separately (Regel A, Sepriano A,
Baraliakos X, et al. Efﬁcacy and safety of non-
pharmacological and non-biological pharmacological
treatment: a systematic literature review informing the
2016 update of the ASAS/EULAR recommendations
for the management of axial spondyloarthritis. Ann
Rheum Dis 2016, submitted for publication).
METHODS
Literature search
The steering group of the ASAS/EULAR task force for
the update of the axSpA management recommendations
(all coauthors) outlined the scope of the literature
search according to the Population, Intervention,
Comparator, Outcomes (PICO) format and deﬁned the
criteria for a study being eligible.12 The population was
deﬁned as adult (≥18 years) patients with axSpA, both
r-axSpA and nr-axSpA. Studies also including patients
with other diagnoses were eligible only if the results for
axSpA were presented separately. The intervention was
deﬁned as any biological drug, including biosimilars
(inﬂiximab, etanercept, adalimumab, golimumab, certo-
lizumab pegol, secukinumab, ustekinumab, tocilizumab,
sarilumab, abatacept, rituximab, all formulations and
treatment duration) or any tsDMARD (apremilast, tofaci-
tinib). The comparator was the same drug (different
dose or regimen), another b/tsDMARD, any non-
biological drug, combination therapy (biological and
non-biological), placebo or ‘none’ (if population-based
incidence rates were reported).
For the efﬁcacy assessment, the following outcomes
were considered: ASAS response criteria (ASAS20,
ASAS40, ASAS5/6 and ASAS partial remission);
Ankylosing Spondylitis Disease Activity Score (ASDAS,
based on C reactive protein; CRP) response criteria
(clinically important improvement (Δ ≥1.1) and major
improvement (Δ ≥2.0)); Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) response (improve-
ment of ≥50% and/or ≥2 units in BASDAI); absolute
change in disease activity measures (pain visual ana-
logue scale, BASDAI, ASDAS and patient global assess-
ment); spine mobility as assessed by the Bath Ankylosing
Spondylitis Metrology Index (BASMI); physical function
as assessed by Bath Ankylosing Spondylitis Functional
Index (BASFI); peripheral manifestations (enthesitis,
swollen joint count and tender joint count (TJC));
radiographic damage (modiﬁed Stoke Ankylosing
Spondylitis Spinal Score (mSASSS), radiographic sacroi-
liitis according to the mNY); inﬂammation on MRI
(active sacroiliitis (ASAS/Outcome Measures in
Rheumatology (OMERACT) deﬁnition), Spondyloarthritis
Research Consortium of Canada (SPARCC)-score (sacro-
iliac joints and spine)); work disability and productivity;
cost-efﬁcacy and cost-effectiveness. For the safety assess-
ment, the following outcomes were considered: withdra-
wals due to adverse events, serious adverse events,
infections, malignancies, cardiovascular diseases, infu-
sion/injection-site reactions, demyelinating diseases, renal
function impairment, gastrointestinal and hepatic adverse
events and haematological abnormalities.
The types of studies considered for inclusion were ran-
domised controlled trials (RCTs), controlled clinical
trials (CCTs) and long-term extensions for efﬁcacy and
safety assessment. Cohort studies were included only for
safety assessment and a minimum of 50 patients per
group was required. Moreover, cohort studies had to
include a comparator group or otherwise report
population-based standardised incidence rates (SIR).
SLRs captured by the search were used to obtain refer-
ences of original studies, which were included if they ful-
ﬁlled the eligibility criteria, but SLRs (except for
Cochrane reviews) were not, in order to avoid duplica-
tion of information.
The following bibliographical databases were
searched: MEDLINE, EMBASE and The Cochrane
Central Register of Controlled Trials (CENTRAL), from
January 2009 until 26 February 2016, without language
restrictions. In order to retrieve additional references,
abstracts from the American College of Rheumatology
(ACR) and EULAR annual conferences for the years
2014 and 2015 were also searched. References from
included studies were screened in order to identify
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further studies for inclusion. If an included abstract was
published in a manuscript before the present paper was
submitted in its ﬁnal format, the data from the manu-
script were used. Details on the search strategy are pro-
vided in online supplementary text 1.
Study selection, data extraction and assessment of risk of
bias
Two reviewers (AS and AR) independently assessed each
title and abstract on suitability for inclusion in the
review, according to the aforementioned selection cri-
teria, followed by a full-text review if necessary. From the
included studies, both reviewers independently extracted
data regarding inclusion and exclusion criteria, main
study design features, characteristics of the study popula-
tion, interventions and outcome measures. The same
two reviewers independently assessed the risk of bias
(RoB) of each included study using The Cochrane
Collaboration’s tool for RCTs and the ‘Hayden-tool’ for
observational studies.13 14 For study selection, extraction
and RoB assessment, disagreements were discussed until
consensus was achieved, and a third reviewer (SR) was
involved whenever necessary.
Data analysis
Heterogeneity in study design and target population pre-
cluded meta-analyses to be performed. The following
measures of treatment effect were calculated to allow, to
the extent possible, comparisons between different
drugs: (1) dichotomous outcomes: risk ratios (RR) and
numbers needed to treat (NNT; number of patients who
must be treated in order to obtain the beneﬁt of interest
in one additional patient); (2) continuous outcomes:
standardised mean differences (SMD; mean difference
between the treatment and placebo for a speciﬁc
outcome divided by the pooled SD).
RESULTS
Of a total of 11 649 references (after de-duplication),
623 were selected for a full-text review. Seventy-six
papers and 24 abstracts on bDMARDs and tsDMARDs
fulﬁlled the inclusion criteria (ﬂow chart in online
supplementary ﬁgure S1). The included publications
stem from a total of 42 different trials, and the majority
of these (30; 71%) included one of the ﬁve TNFi. In
addition, we have included one trial for each the new
bDMARDs and tsDMARDs (see online supplementary
table S1). Patients with r-axSpA according to the mNY
were included in most trials (30; 71%). Patients with
axSpA according to the ASAS criteria were included in 9
(21%); four of these included only nr-axSpA and one
included both patients with r-axSpA and nr-axSpA (see
online supplementary table S1.1). In addition, seven
observational studies assessing TNFi long-term safety
were identiﬁed (see online supplementary table S2) as
well as one Cochrane review on TNFi efﬁcacy and safety.
TNF inhibitors
A Cochrane meta-analysis of 18 RCTs (up to November
2014) had shown that, compared with placebo, patients
with r-axSpA treated with TNFi (certolizumab pegol not
included) were signiﬁcantly more likely to achieve an
ASAS40 response at 6 months (NNT range: 3–5).15
Similarly, good results had been found for improvement
in physical function as measured by BASFI (SMD range:
1.1–2.1) and for reduction in spine inﬂammation as
measured by the MRI SPARCC spine score (absolute
increased beneﬁt range: −2.5–−6%).
In the current SLR, RCTs on the full spectrum of
axSpA were included (see online supplementary tables
S3–S34).16–28 Given the time span (2009–2016) of the
SLR, the main phase 3 RCTs for etanercept, inﬂiximab,
adalimumab and golimumab in r-axSpA were not
included, but only their LTE or other (subsequent)
trials in different populations. These relevant data,
included in previous SLRs,8 10 are therefore also shown
in table 1 together with the new evidence.29–33 The treat-
ment effect on ASAS40 was large both for r-axSpA
(response rate range from 2009 onwards: 44.5% to
47.7% (NNT range: 2.6–5.2); response rate range before
2009: 39.4–54.3% (NNT: 2.6–3.8)) and nr-axSpA
(response rate range: 33.3–61.1%; NNT range: 2.3–5.4)
(table 1 and table 2). The RAPID-axSpA is the only trial
including both patients with r-axSpA and nr-axSpA with
either positive CRP or MRI (with stratiﬁed randomisa-
tion for the presence of radiographic sacroiliitis).18 In
this study, largely overlapping results were observed
between the two groups for ASAS20 and ASAS40, but
the improvement in disability (BASFI) was greater for
patients with nr-axSpA (SMD (95% CI): 1.02 (0.59 to
1.44)) as compared to those with r-axSpA (SMD (95%
CI) 0.65 (0.28 to 1.01)).
In three separate trials, the treatment effect of etaner-
cept, adalimumab and golimumab in patients with
nr-axSpA was tested according to the MRI/CRP status at
treatment start (table 3).24 26 27 For all drugs, the effect
on ASAS20 and ASAS40 responses was far smaller (and
not statistically signiﬁcant) in patients with a normal
CRP and MRI at baseline (NNT range: 2.5–33.3). In
patients who had a positive MRI or an increased CRP
(adalimumab and golimumab) and in patients who had
both (etanercept), the effect sizes were far greater and
statistically signiﬁcant (NNT range: 2.5–4.7).
TNFi have also shown good results for other out-
comes, including ASDAS, BASDAI, CRP, TJC, spine
mobility and axial inﬂammation on MRI (see online
supplementary tables S3–S34). In addition, long-term
extension studies of trials in r-axSpA have revealed high
retention rates after 2 years (range: 71–81%), 5 years
(range: 55–69%) and 8 years (48%) (see online
supplementary table S33).
In the aforementioned Cochrane review,15 a
meta-analysis of all the TNFi combined against placebo
(16 studies) has shown an increased risk of withdrawal
due to adverse events in the TNFi group (Peto’s OR
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Table 1 Effect of TNFi on ASAS20, ASAS40 and BASFI in patients with r-axSpA (mNY) (RCTs)
<2009 (previous SLRs)8 10 ≥2009 (current SLR)
Outcome
Drug N patients (Study)
Time-point
(weeks)
Response
treatment
(%)
Response
placebo (%) RR (95% CI) NNT
N patients
(Study)
Time-point
(weeks)
Response
treatment
(%)
Response
placebo (%) RR (95% CI) NNT
ASAS20
Etanercept 40 (Gorman et al29) 16 80 30 2.67 (1.32 to 5.39) 2.0 81 (Dijkmans 200916) 12 60.0 23.0 2.61 (1.36 to 4.52) 2.7
277 (Davis et al 30) 24 57 22 2.59 (1.80 to 3.57) 2.9 82 (SPINE17) 12 68.4 35.9 1.91 (1.21 to 3.21) 3.1
Infliximab 279 (ASSERT31) 24 61.2 19.2 3.18 (2.00 to 5.08) 2.4 76 (Inman 201018) 12 54.0 31.0 1.74 (1.02 to 3.22) 4.3
Adalimumab 315 (ATLAS32) 12 58.2 20.6 2.83 (1.92 to 4.18) 2.7 261 (Huang 201419) 12 67.2 30.4 2.21 (1.78 to 3.29) 2.7
Golimumab 216* (GO-RAISE33) 14 59.4 21.8 2.73 (1.75 to 4.24) 2.7 213 (Bao 201420) 24 50.0 22.9 2.18 (1.55 to 3.45) 3.7
41 (Tam 201421) 24 55.0 14.0 3.93 (1.26 to 11.80) 2.4
Certolizumab NA NA NA NA NA NA 122† (RAPID-axSpA22) 24 67.7 33.3 2.03 (1.36 to 3.04) 2.9
ASAS40
Etanercept – – – – – – 82 (SPINE17) 12 44.7 25.6 1.75 (0.99 to 3.59) 5.2
Infliximab 279 (ASSERT31) 24 47.0 12.0 3.92 (2.13 to 7.55) 2.9 76 (Inman 201018) 12 46.0 8.0 5.75 (1.83 to 17.74) 2.6
Adalimumab 315 (ATLAS32) 12 39.4 13.1 3.01 (1.82 to 5.11) 3.8 344 (Huang 201419) 12 44.5 9.6 4.64 (2.61 to 8.32) 2.9
Golimumab 216* (GO-RAISE33) 24 54.3 15.4 3.53 (2.05 to 6.08) 2.6 – – – – – –
Certolizumab NA NA NA NA NA NA 122† (RAPID-axSpA22) 24 47.7 15.8 3.02 (1.57 to 5.79) 3.1
N patients (Study)
Time point
(weeks)
Impr.
treatment
mean (SD)
Impr.
placebo
mean (SD) SMD (95% CI) N patients (Study)
Time point
(weeks)
Impr.
treatment
mean (SD)
Impr.
placebo
mean (SD) SMD (95% CI)
BASFI (Δ‡)
Etanercept 40 (Gorman et al 29) 16 2.3 (−) 0.1 (−) n/e 40 (Barkham 201023) 12 1.35 (−) −0.21 (−) n/e
277 (Davis et al 30) 24 1.6 (−) 0.2 (−) n/e 82 (SPINE17) 12 2.20 (1.8) 1.00 (1.8) 0.19 (−1.31 to 1.68)
Infliximab 279 (ASSERT31) 24 1.7 (−) 0.0 (−) n/e – – – – –
Adalimumab 315 (ATLAS32) – – – – 261 (Huang 201419) 12 1.8 (2.0) 0.47 (1.6) 0.69 (0.46 to 0.92)
315 (ATLAS24) 24 2.00 (−) 0.50 (−) n/e
Golimumab 216† (GO-RAISE33) 24 1.6 (−) −0.4 (−) n/e 213 (Bao 201420) 24 1.26 (2.6) −0.11 (2.1) 0.58 (0.30 to 0.85)
41 (Tam 201421) 24 1.27 (2.5) −1.73 (7.2) 0.55 (−0.08 to 1.16)
Certolizumab NA NA NA NA NA 122† (RAPID-axSpA22) 24 2.30 (2.4) 0.90 (1.8) 0.65 (0.28 to 1.01)
*Golimumab 50 mg versus placebo.
†Certolizumab pegol 200 mg versus placebo.
‡Mean improvement compared to baseline value (range: 0–10).
r-axSpA, radiographic axial spondyloarthritis; mNY, modified New York criteria; NNT, number needed to treat; RR, risk ratio; SMD, standardised mean difference; n/e, not possible to estimate;
Impr, improvement; ASAS, Assessment of SpondyloArthritis international Society; BASFI, Bath Ankylosing Spondylitis Functional Index NA, not applicable.
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(pOR): 2.44 (1.26 to 4.72)) but not for serious adverse
events (pOR: 1.45 (0.85 to 2.48). Data from RCTs
included in the current review do not indicate new and
unknown safety signals for TNFi (see online
supplementary tables S35–S44).
We identiﬁed seven observational cohort studies asses-
sing TNFi long-term safety (table 4; and online
supplementary tables S45–S56). Three studies (at mod-
erate RoB) revealed no increased risk of malignancies as
compared to the general population.34–36 Two studies
(at low RoB) showed no increased risk of infections in
TNFi users versus non-users (adjusted OR (95% CI) 1.25
(0.90 to 1.73);37 adjusted HR (95% CI) 1.05 (0.45 to
2.45)).38 In both studies, the estimates were adjusted for
concomitant use of glucocorticoids, conventional syn-
thetic DMARDs (csDMARDs) and comorbidities. Finally,
we found conﬂicting data concerning the risk of tuber-
culosis in two studies at moderate RoB. One study has
shown an increased risk in TNFi-treated patients com-
pared to non-treated patients (unadjusted HR: 4.9 (1.5
to 15.4)),40 while another study did not (unadjusted
HR: 0.53 (0.14 to 1.91)).39
bDMARDs and tsDMARDs targeting new pathways
A detailed description of each study’s main character-
istics as well as all efﬁcacy and safety outcomes is shown
in online supplementary tables S57–S65. Two large
16-week RCTs (MEASURE-1 and MEASURE-2) assessed
the effect of secukinumab (a subcutaneous IL-17 inhibi-
tor) in patients with r-axSpA (both TNFi-naïve and after
failure to at least one TNFi).41 Secukinumab 150 mg has
proven to be effective in both studies (ASAS40 response
rate 42% (NNT: 3.4) and 36% (NNT: 4.0) for
MEAURE-1 and MEASURE-2 respectively). Positive
results with a lower dose (75 mg) were only found in
MEASURE-1 after an intravenous loading dose (table 5).
Large treatment effects were also seen for other disease
domains, including axial inﬂammation and quality of
life (see online supplementary tables S61–S65).
TNFi-naïve patients have shown better response rates
than TNFi-experienced patients, but beneﬁcial effects
were also seen in these latter patients (ASAS 40 response
rate for secukinumab 150 mg: 43.2% (NNT: 3.9) for
TNFi-naïve and 25.0% (NNT: 4.0) for TNFi-experienced
patients).49
New cases and reactivations of Crohn’s disease were
observed (5 cases in both studies; pooled incidence rate:
0.7/100 patient-years) irrespective of the dose (see
online supplementary table S64), but other relevant
safety signals were not found.
In a 24-week uncontrolled and open label (high risk
of bias) proof of concept (POC) trial, ustekinumab
(IL-12/IL-23 inhibitor) has shown preliminary good
results (ASAS20 at week 24: 75%) in TNFi-naive patients
with long-standing r-axSpA.42 Tofacitinib ( Janus kinase
inhibitor) has been tested in a phase 2 double-blind
Table 2 Effect of TNFi on ASAS20, ASAS40 and BASFI in patients with nr-axSpA (ASAS criteria) (RCTs)
Outcome
Drug N patients (Study)
Time point
(weeks)
Response
treatment (%)
Response
placebo (%) RR (95% CI) NNT
ASAS20
Etanercept 215 (EMBARK25) 12 52.4 36.1 1.45 (1.06 to 1.90) 6.1
Infliximab* – – – – – –
Adalimumab 185 (ABILITY-127) 12 51.6 30.9 1.67 (1.17 to 2.40) 4.8
Golimumab 198 (GO-AHEAD28) 16 71.1 40.0 1.78 (1.43 to 2.43) 3.2
Certolizumab 96† (RAPID-axSpA22) 24 65.2 24.0 2.72 (1.59 to 4.65) 2.4
ASAS40
Etanercept 215 (EMBARK25) 12 33.3 14.8 2.25 (1.33 to 3.81) 5.4
Infliximab* 40 (Barkham 200926) 16 61.1 17.6 3.47 (1.16 to 10.31) 2.3
Adalimumab 185 (ABILITY-127) 12 36.3 14.9 2.44 (1.40 to 4.25) 4.7
Golimumab 198 (GO-AHEAD28) 16 56.7 23.0 2.47 (1.67 to 3.70) 3.0
Certolizumab 96† (RAPID-axSpA22) 24 56.5 14.0 4.04 (1.94 to 8.40) 2.7
Impr. mean (SD) Impr. mean (SD) SMD (95% CI)
BASFI (Δ‡)
Etanercept 215 (EMBARK25) 12 1.40 (0.2) 0.80 (0.2) 3.00 (2.61 to 3.39)
Infliximab* 40 (Barkham 200926) 16 2.70 (2.36) 0.47 (2.25) 0.97 (0.31 to 1.62)
Adalimumab 185 (ABILITY-127) 12 1.10 (−) 0.60 (−) n/e
Golimumab – – – – –
Certolizumab 96† (RAPID-axSpA22) 24 2.50 (2.4) 0.10 (2.3) 1.02 (0.59 to 1.44)
*nr-axSpA defined by: inflammatory back pain (Calin definition) within 3 months to 3 years AND sacroiliitis on MRI AND HLA-B27 positivity.
†Certolizumab pegol 200 mg versus placebo.
‡Mean improvement compared to baseline value (range: 0–10).
ASAS, Assessment in SpondyloArthritis international Society; BASFI, Bath Ankylosing Spondylitis Functional Index; HLA, human leucocyte
antigen; Impr, improvement; NA, not applicable; n/e, not possible to estimate; nr-axSpA, non-radiographic axial spondyloarthritis; NNT,
number needed to treat; RR, risk ratio; SMD, standardised mean difference.
Sepriano A, et al. RMD Open 2017;3:e000396. doi:10.1136/rmdopen-2016-000396 5
Spondyloarthritis
group.bmj.com on March 31, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
RCT43 and has suggested beneﬁcial effects in various
outcome measures, which were statistically signiﬁcant for
both the 5 mg and 10 mg twice a day doses, and with a
clear dose–response in the objective outcome measures.
As shown in table 5, phase 2 and POC trials with drugs
aiming at other treatment targets did not suggest beneﬁts.
These drugs included a phosphodiesterase-4 inhibitor
(apremilast),44 a CD20 (B-cell) inhibitor (rituximab),45
two IL-6 inhibitors (tocilizumab and sarilumab)46 47 and
a T-cell costimulation inhibitor (abatacept).48
Trials with an active comparator
One small (n=50) and underpowered head-to-head,
open-label (high RoB) trial has compared two TNFi and
did not show statistically signiﬁcant differences in the
main efﬁcacy outcomes between inﬂiximab and etaner-
cept at week 12 (ASAS20: 75% vs 60%; ASAS40: 55 vs
43%; p>0.05 for both).50
Two randomised trials have compared etanercept to
sulfasalazine (both without a placebo group): the
ASCEND (double-blind) trial and the ESTHER (open-
label) trial, in established (>5 years) and early axSpA,
respectively.51 52 Etanercept was superior to sulfasalazine
and similarly safe, both in r-axSpA and nr-axSpA,53 and in
patients with (ASAS20: 69% vs 50%; p=0.02) and without
(ASAS20: 79% vs 55%; p<0.001) peripheral arthritis.54
The INFAST trial (n=156) has shown that combination
therapy with inﬂiximab and naproxen is superior to
naproxen alone in TNFi-naïve early patients with axSpA
(not refractory to NSAIDs).55
Two small (n=30 and n=60) open-label POC studies
have compared TNFi and bisphosphonates and have
suggested a larger reduction in disability and objective
signs of inﬂammation for the TNFi.56 57
Finally, a non-inferiority RCT (PLANETAS) has shown
comparable efﬁcacy and safety proﬁles between an
inﬂiximab biosimilar (CT-P13) and an inﬂiximab origin-
ator sustained up to 54 weeks of treatment.58 59 Details
can be found in table 6 and online supplementary
tables S66–S73.
Strategy trials
A high level of heterogeneity in terms of study design
and deﬁnitions of remission, response and ﬂare was
found in the included strategy trials (seeonline
supplementary tables S74–S80). Studies assessing stop-
ping treatment have shown that ﬂare or loss of previous
response status occurred fast (within 14–40 weeks) in
the majority of patients (69–79%) and that restart of
treatment failed to restore previous status in a substantial
proportion of patients (33–73%).60 61 In one study, a
ﬂare was unlikely after stopping treatment (2.5% vs
7.5%; p=0.62), but more than 50% lost their previous
state of remission after follow-up.62
Two dose-tapering strategies were tested in two open-
label RCTs and have suggested that dose reduction
decreases the proportion of patients still responding to
the drug (52.2% vs 91.7%),63 but that carefully increasing
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Table 4 Safety outcomes for TNFi on observational studies
Study Treatment group N patients
Exposition
patient-years N events IR /100,000py
Effect size
Ratio*
(95% CI) SIR† (95% CI) Risk of bias
Malignancies
Carmona et al34 Treated (3 TNFi‡) 761 2288 – – – 0.92 (0.44 to 1.70) Moderate
General population NA NA NA NA
Dreyer et al35 Treated (3 TNFi‡) 861 – 8 – – 0.82 (0.41 to 1.64) Moderate
General population NA NA NA –
Westhovens et al36 Treated (females) (4 TNFi‡) 74 1194 – 770.1 – 1.54 Moderate
General population (females) NA (overall) – 499.1 REF
Treated (males) (4 TNFi‡) 157 – 370.2 1.31
General population (males) NA – 283.4 REF
Infections
Wallis37 Any TNFi§ 264 684 127 19/100py 1.25 (0.90 to 1.73)¶ – Low
no-TNFi 186 651 91 14/100py REF
Moura et al38 TNFi§ (±csDMARDs) 714 – 57 2.44/100py 1.05 (0.45 to 2,45)** – Low
Only csDMARDs (overall) (overall) 4.12/100py 1.77 (0.78 to 4,02)**
None 2.25/100py REF
Tuberculosis
Kim et al39 Any TNFi 354 1784 3 561 0.53 (0.14: 1.91)†† – Moderate
Infliximab 78 366 2 540 1.57 (0.34 to 7.18) ††
Adalimumab 66 204 1 308 1.33 (0.17 to 10.44)††
Etanercept 210 1214 0 0 NA
Controls 909 3247 10 308 REF
Kim et al40 Treated (5 TNFi‡) 336 1166 7 600.2 4.9 (1.5 to 15.4)†† – Moderate
Controls 986 – – 123.1 REF
*Different effect sizes/ratios are provided in the different studies.
†SIR, Standardised Incidence Ratio (the ratio between observed and expected cases during follow-up).
‡3 TNFi (etanercept, infliximab, adalimumab), 4 TNFi (etanercept, infliximab, adalimumab, golimumab), 5 TNFi (etanercept, infliximab, adalimumab, golimumab, certolizumab);.
§Not specified;.
¶aOR: adjusted OR (adjusted for: age, disease duration, smoking, csDMARDs, oral steroids, BASDAI, BASFI, comorbidity score, hospitalisation);.
**aHR, adjusted HR (adjusted for baseline patient sociodemographics, comorbidities, prior health service use, time dependent use of NSAIDs, and corticosteroids);.
††Unadjusted HR;.
IR, incidence rate; NA, not applicable; py, patient-years; REF, reference group; TNFi, tumour necrosis factor inhibitors.
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Table 5 Effect of new biological and targeted-synthetic DMARDs on ASAS20 and ASAS40 responses in patients with axSpA
Drug
Study reference Study design Types of patients Treatment groups
N
patients
Time
point
(weeks)
ASAS20
(%)
p
Value
NNT
ASAS20
ASAS40
(%) p Value
NNT
ASAS40
Risk of
bias
Secukinumab
Baeten et al41
(MEASURE-1†)
Phase 3 RCT
double-blind
r-axSpA* TNFi-naïve and
TNFi-failure (≤1 TNFi)
150 mg Q4W SC 125 16 61 <0.01 3.1 42 <0.01 3.4 Low
75 mg Q4W SC 124 16 60 <0.01 3.2 33 <0.01 5.0
Placebo 122 16 29 REF REF 13 REF REF
Secukinumab
Baeten et al41
(MEASURE-2†)
Phase 3 RCT
double-blind
r-axSpA* TNFi-naïve and
TNFi-failure (≤1 TNFi)
150 mg Q4W SC 72 16 61 <0.01 3.0 36 <0.01 4.0 Low
75 mg Q4W SC 73 16 41 NS 7.7 26 NS 6.7
Placebo 74 16 28 REF REF 11 REF REF
Ustekinumab
Poddubnyy
et al42 (TOPAS)
POC
non-controlled
open-label trial
r-axSpA* TNFi-naïve only 90 mg SC 20 24 75 NA NA 65 NA NA High
Tofacitinib
van der Heijde
et al43
Phase 2 RCT
double-blind
r-axSpA* TNFi-naïve only 2 mg two times a day oral 52 12 51.9 NS 9.3 42.3 <0.05 4.4 Low
5 mg two times a day oral 52 12 80.8 <0.001 2.5 46.2 <0.01 3.8
10 mg two times a day oral 52 12 55.8 NS 6.8 38.5 <0.05 5.3
Placebo 51 12 41.2 REF REF 19.6 REF REF
Apremilast
Pathan et al44
Phase 2 RCT
double-blind
r-axSpA* TNFi-naïve only 30 mg two times a day oral 17 12 35.3 0.25 5.1 23.5 0.17 5.5 Low
Placebo 19 12 15.8 REF REF 5.3 REF REF
Rituximab
Song et al45
POC
non-controlled
open-label trial
r-axSpA* TNFi-naïve and
TNFi-failure (≥1 TNFi)
1000 mg IV 20 24 40 – NA 25 – NA High
TNFi-naïve 10 24 50 – NA 40 – NA
TNFi-failure 10 24 30 – NA 10 – NA
Tocilizumab
Sieper et al46
(BUILDER-1)
Phase 2 RCT
double-blind
r-axSpA* TNFi-naïve only TCZ 8 mg/Kg Q4W IV 51 12 37.3 NS 10.2 11.8 NS 12.8 Low
Placebo 51 12 27.5 REF REF 19.6 REF REF
Sarilumab
Sieper et al
ARD47
(ALIGN)
Phase 2 RCT
double-blind
r-axSpA* TNFi-naïve only SAR 100 mg Q2W SC 49 12 24.5 NS 200 14.3 NS 15.9 Low
SAR 150 mg Q2W SC 50 12 30.0 NS 16.7 16.0 NS 12.5
SAR 100 mg QW SC 52 12 19.2 NS 20.8 5.8 NS 45.5
SAR 200 mg Q2W SC 50 12 30.0 NS 16.7 18.0 NS 10.0
SAR 150 mg QW SC 50 12 38.0 NS 7.1 20.0 NS 8.3
Placebo 50 12 24.0 REF REF 8.0 REF REF
Abatacept
Song et al48
POC
non-controlled
open-label trial
r-axSpA* TNFi-naïve and
TNFi-failure
ABA10 mg/Kg Q28D IV
(TNFi-naive)
15 24 26.7 – NA 13.3 – NA Low
ABA 10 mg/Kg Q28D IV
(TNFi-failure)
15 24 20 NA 0 NA
*According to the modified New York criteria.
†Loading dose in MEASURE-1: 10 mg/kg IV 0, 2, 4 weeks and MEASURE 2: 150/75 mg SC 0, 1, 2, 3 weeks.
ASAS, Assessment in SpondyloArthritis international Society; two times a day, twice a day; IV, intravenous; NA, not applicable; NNT, number needed to treat; NS, non-significant (p>0.05);
POC, proof of concept; Q28D, every 28 days; Q2W, every 2 weeks; Q4W, every 4 weeks; QW, every week; r-axSpA, radiographic axial spondyloarthritis; RCT, randomised clinical trial; REF,
reference group; SC, subcutaneous; TNFi, tumour necrosis factor inhibitor.
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the administration interval (‘spacing’) may yield similar
numbers of patients still in remission after follow-up as
compared to the standard strategy (90% vs 86%).64
DISCUSSION
This systematic literature review conﬁrms the efﬁcacy
and safety of TNFi (including the new data on certolizu-
mab pegol) in patients with r-axSpA. Efﬁcacy was also
established in patients with nr-axSpA, especially in those
who have objective signs of inﬂammation (either CRP
and/or MRI positivity). bDMARDs and tsDMARDs tar-
geting pathways other than TNFi have so far only been
tested in patients with r-axSpA, and secukinumab is the
ﬁrst IL17-inhibiting drug with proven efﬁcacy and safety
in phase 3 trials. CT-P13, an inﬂiximab biosimilar, has
been shown to be as effective and safe as an inﬂiximab
originator in patients with r-axSpA. Preliminary data
suggest that TNFi dose tapering may be attainable, but
stopping treatment results in unacceptable high rates of
disease ﬂares.
Many high-quality placebo-controlled trials have
proven the short-term efﬁcacy of TNFi in patients with
axSpA. This review suggests that treatment effects across
the different TNFi are similar (ASAS40 NNT range: 2.6–
5.2), but a valid comparison across drugs cannot be
made in the absence of proper head-to-head trials.
Differences in study design, patient characteristics and
methodological quality may cause differences in treat-
ment effects that cannot be attributed to the tested
drugs themselves.65 Formal head-to-head RCTs including
treatments with different modes of action are warranted
to draw deﬁnite conclusions, since indirect comparisons,
albeit fancy, are methodologically ﬂawed and do not
allow prioritisation of treatments.
Of note, TNFi are effective in patients with long-
standing r-axSpA and in those with nr-axSpA. Only one
trial (RAPID-axSpA) included both patients with
nr-axSpA and r-axSpA. This study, in which all patients
had to have either positive CRP or MRI, yielded similar
treatment effects for the two groups on several disease
activity outcomes (eg, ASAS40). Congruent with expecta-
tions, reduction of disability (as measured by BASFI) was
larger in patients with nr-axSpA as compared to those
with r-axSpA.
Contrasting with RAPID-axSpA, in three trials per-
formed solely in patients with nr-axSpA, CRP positivity
and MRI inﬂammation were not mandatory for inclu-
sion. Subgroup analyses comparing patients with these
objective signs of inﬂammation to those without revealed
signiﬁcantly better treatment effects in the former.
These results were at the basis of the requirement of
these objective signs of inﬂammation in patients with
nr-axSpA to be considered for treatment with TNFi.66 67
Placebo-controlled safety analyses from RCTs are ham-
pered by a low expected number of events occurring
during a short follow-up in patients selected by restrict-
ive inclusion criteria. Observational studies may yield
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valuable information on drug safety in ‘real-world’
patients, if well analysed. In axSpA, studies are still very
scarce. We could include seven studies which did not
reveal new safety signals. Obviously, these positive results
should be interpreted in the context of the fact that
careful screening and selection of patients by treating
rheumatologists was at the basis of these studies.
For long, treatment options in patients with inad-
equate response to TNFi were limited. Recently, several
new drugs have been tested. IL-17 blockade by secukinu-
mab proved to be effective in patients with r-axSpA,
both naïve or previously exposed to TNFi therapy. This
represents important progress in the management of
patients with axSpA, particularly of those who have
failed TNFi and now have an alternative option. Of
note, for psoriasis, in the light of the results of two
head-to-head trials (secukinumab 300 mg compared to
etanercept and to ustekinumab), secukinumab is
approved as a ﬁrst-line systemic treatment for adults with
moderate-to-severe plaque psoriasis.68 69 Safety data on
secukinumab are still limited, but the overall acceptable
safety proﬁle in RCTs is good. However, exacerbations
(or new onset) of Crohn’s disease with secukinumab
deserve attention from clinicians. In fact, IL-17 inhib-
ition is not considered a therapeutic option in Crohn’s
disease anymore, given the results of one trial,70 and this
should be taken into account when treating patients
with axSpA who have concomitant Crohn’s disease. The
promising (yet preliminary) effects of ustekinumab in
r-axSpA in a POC trial included in this SLR suggests
that, contrary to rheumatoid arthritis, targeting the
IL-23-IL-17 axis may be effective in patients with axSpA.
Ustekinumab was also efﬁcacious in patients with psoria-
sis and Crohn’s disease.71 72
Tofacitinib (a tsDMARD targeting Janus kinase) has
tested positively in a phase 2 RCT. Other treatment
targets are less promising: Apremilast has shown
rather poor efﬁcacy in a phase 2 trial and preliminary
(but still unpublished) reports from one phase 3 RCT
suggest a failure of apremilast to meet the primary
end point (ASAS 20 at week 16).73 Deﬁnitive conclu-
sions on the role of bisphosphonates on the manage-
ment of axSpA are hampered by study design
shortcomings (eg, absence of a placebo group), and
results from these trials are difﬁcult to interpret and
not convincing.
Stopping treatment with TNFi early in the disease
course was so far tested in three studies which have
shown that individual patients may achieve sustained
drug-free remission but that, at the group level, the pro-
portion of patients losing their previous good response
is large and remission is not easily regained after resum-
ing TNFi treatment. Careful spacing (increasing the
interval) may lead to acceptable long-term outcomes.
However, reliable information about which patients may
apply for tapering is still lacking.
In summary, this SLR has documented that patients
with the entire spectrum of axial SpA can be treated
effectively and safely with several bDMARDs, that the
options rapidly expand and that several tsDMARDs are
in development for the treatment of axSpA.
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